Passage Bio Narrows Losses, Boosts Cash Amid R&D Cuts

Ticker: PASG · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1787297

Sentiment: mixed

Topics: Biotechnology, Gene Therapy, Neurodegenerative Diseases, Financial Performance, Cash Burn, R&D Spending, Liquidity Risk

Related Tickers: PASG

TL;DR

**PASG is cutting costs and building cash, but the R&D slowdown could signal a longer road to market for its pipeline.**

AI Summary

Passage BIO, Inc. reported a net loss of $9.385 million for the three months ended June 30, 2025, a significant improvement from the $15.991 million net loss in the same period of 2024, representing a 41.3% reduction. For the six months ended June 30, 2025, the net loss was $24.790 million, down from $32.702 million in 2024, a 24.2% decrease. Research and development expenses decreased substantially, falling to $5.814 million for the three months ended June 30, 2025, from $10.430 million in 2024, and to $13.551 million for the six months ended June 30, 2025, from $21.965 million in 2024. General and administrative expenses also saw reductions, from $6.510 million to $4.520 million for the quarter and from $13.025 million to $10.605 million for the six-month period. The company's cash and cash equivalents increased to $57.626 million as of June 30, 2025, from $37.573 million at December 31, 2024, primarily due to $40.216 million in cash provided by investing activities, including sales or maturities of marketable securities totaling $39.046 million. An accumulated deficit of $684.0 million as of June 30, 2025, indicates ongoing losses, and the company acknowledges the need for substantial additional capital to fund operations and product development, with $15.8 million remaining available under its ATM Facility.

Why It Matters

Passage Bio's reduced net loss and increased cash position are critical for investors, signaling improved financial management in a challenging biotech landscape. The significant cuts in R&D expenses, while improving the bottom line, could raise questions among investors about the pace of pipeline development, especially for its lead candidate PBFT02 for FTD-GRN. For employees, these shifts might imply a more focused operational strategy, potentially impacting job security or departmental priorities. Customers and the broader market, particularly those affected by neurodegenerative diseases, will be watching closely to see if these financial adjustments enable sustained progress in bringing new therapies to market, especially given the competitive pressures from larger pharmaceutical companies in gene therapy development.

Risk Assessment

Risk Level: high — Passage Bio has an accumulated deficit of $684.0 million as of June 30, 2025, and has incurred recurring losses and negative cash flows from operations since inception. The company explicitly states that 'Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates,' indicating significant future financing risk.

Analyst Insight

Investors should closely monitor Passage Bio's capital raise efforts and the strategic implications of its reduced R&D spending. While cost control is positive, the long-term viability hinges on successful clinical trials and securing additional funding, making this a speculative investment.

Financial Highlights

debt To Equity
1.07
revenue
$0
operating Margin
N/A
total Assets
$79.198M
total Debt
$40.940M
net Income
-$9.385M
eps
-$2.96
gross Margin
N/A
cash Position
$57.626M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were Passage Bio's net losses for the second quarter and first half of 2025?

Passage Bio reported a net loss of $9.385 million for the three months ended June 30, 2025, and a net loss of $24.790 million for the six months ended June 30, 2025.

How did Passage Bio's research and development expenses change in Q2 2025 compared to Q2 2024?

Research and development expenses for Passage Bio decreased to $5.814 million in Q2 2025 from $10.430 million in Q2 2024, representing a significant reduction.

What is Passage Bio's current cash and cash equivalents position?

As of June 30, 2025, Passage Bio had $57.626 million in cash and cash equivalents, an increase from $37.573 million at December 31, 2024.

Does Passage Bio have sufficient capital to fund its operations for the next year?

Passage Bio expects its cash and cash equivalents to be sufficient to fund forecasted operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of the financial statements.

What is Passage Bio's accumulated deficit as of June 30, 2025?

Passage Bio had an accumulated deficit of $684.0 million as of June 30, 2025, reflecting recurring losses since its inception.

What is Passage Bio's lead clinical product candidate?

Passage Bio's lead clinical product candidate is PBFT02, which is being developed for the treatment of frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN).

What is the remaining capacity under Passage Bio's ATM Facility?

As of June 30, 2025, Passage Bio has $15.8 million of capacity remaining available to be sold under its At-The-Market (ATM) Facility.

What risks does Passage Bio highlight regarding its future funding?

Passage Bio states it may not be able to obtain additional financing on acceptable terms, or at all, and could be required to delay, reduce, or eliminate research and development programs if funding is unfavorable.

When did Passage Bio effect its reverse stock split and what was the ratio?

Passage Bio effected a 1-for-20 reverse stock split of its common stock on July 14, 2025, to regain compliance with Nasdaq's listing requirements.

What is Passage Bio's primary business focus?

Passage Bio's primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathology in neurodegenerative diseases.

Risk Factors

Industry Context

Passage BIO operates in the highly competitive and rapidly evolving gene therapy sector. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Companies in this space often rely on strategic partnerships and substantial capital raises to fund their pipeline development.

Regulatory Implications

The gene therapy field faces intense regulatory scrutiny. Passage BIO must navigate complex approval processes with agencies like the FDA, where evolving guidelines for safety, efficacy, and manufacturing can impact development timelines and market access.

What Investors Should Do

  1. Monitor cash burn and future financing needs.
  2. Evaluate R&D pipeline progress and clinical trial results.
  3. Assess the impact of reduced operating expenses.

Key Dates

Glossary

Accumulated deficit
The total net losses of a company since its inception, minus any net profits. It represents the cumulative losses that have not been offset by profits. (Indicates the company has historically operated at a loss, with a significant deficit of $684.0 million as of June 30, 2025.)
ATM Facility
At-the-Market equity offering facility. This allows a company to sell shares of its stock over time at prevailing market prices. (Passage BIO has $15.8 million remaining under its ATM Facility, which can be used to raise additional capital.)
Marketable securities
Investments that are easily bought or sold on a public exchange, such as stocks and bonds. They are typically held as short-term investments. (The company had $39.183 million in marketable securities at December 31, 2024, and their sale or maturity provided $39.046 million in cash during the period.)
Reverse stock split
A corporate action to reduce the number of outstanding shares of stock by consolidating them into fewer, proportionally more valuable shares. (The number of common shares outstanding (3,178,710 as of August 7, 2025) is adjusted for a 1-for-20 reverse stock split, impacting per-share calculations.)

Year-Over-Year Comparison

Passage BIO has significantly reduced its net loss for both the quarter (41.3% decrease) and year-to-date (24.2% decrease) compared to the prior year, driven by substantial cuts in R&D and G&A expenses. While total assets have decreased from $102.4 million to $79.2 million, cash position has strengthened to $57.6 million from $37.6 million due to strategic sales of marketable securities. The accumulated deficit continues to grow, underscoring the ongoing need for capital.

Filing Stats: 4,526 words · 18 min read · ~15 pages · Grade level 17.1 · Accepted 2025-08-12 07:15:57

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41 PART II. OTHER INFORMATION 42 Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 95 Item 3. Defaults Upon Senior Securities 95 Item 4. Mine Safety Disclosures 95 Item 5. Other Information 95 Item 6. Exhibits 96

Signatures

Signatures 98 3 Table of Contents

-FINANCIAL INFORMATION

PART I-FINANCIAL INFORMATION

Interim Financial Statements

Item 1. Interim Financial Statements. Passage Bio, Inc. Balance Sheets (Unaudited) (in thousands, except share and per share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 57,626 $ 37,573 Marketable securities — 39,183 Prepaid expenses and other current assets 1,402 838 Prepaid research and development 1,287 1,221 Total current assets 60,315 78,815 Property and equipment, net 5,340 9,331 Right of use assets - operating leases 13,273 13,803 Other assets 270 463 Total assets $ 79,198 $ 102,412 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,395 $ 742 Accrued expenses and other current liabilities 4,073 6,707 Non-refundable sublicense and transition services payments received 9,741 8,226 Operating lease liabilities 3,592 3,688 Total current liabilities 19,801 19,363 Operating lease liabilities - noncurrent 21,139 21,788 Total liabilities 40,940 41,151 Commitments and contingencies (note 11) Stockholders' equity: Preferred stock, $ 0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both June 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value: 300,000,000 shares authorized; 3,178,710 shares issued and outstanding at June 30, 2025 and 3,161,503 shares issued and outstanding at December 31, 2024 — — Additional paidin capital 722,283 720,488 Accumulated other comprehensive income (loss) — 8 Accumulated deficit ( 684,025 ) ( 659,235 ) Total stockholders' equity 38,258 61,261 Total liabilities and stockholders' equity $ 79,198 $ 102,412 See accompanying notes to unaudited interim financial statements. 4 Table of Contents Passage Bio, Inc. (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share data) 2025

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing